Suppression of early experimental osteoarthritis by in vivo delivery of the adenoviral vector-mediated NF-κBp65-specific siRNA

Osteoarthritis and Cartilage

Volumn 16, Issue 2, 2008, Pages 174-184

  Chen, L X ^a   Lin, L ^a   Wang, H J ^a   Wei, X L ^a   Fu, X ^a   Zhang, J Y ^a   Yu, C L ^a  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

Author keywords

Adenoviral vector; IL 1 ; NF Bp65; Osteoarthritis; siRNA; TNF

Indexed keywords

ACETYLSALICYLIC ACID; ADENOVIRUS VECTOR; INTERLEUKIN 1BETA; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ARTICULAR CARTILAGE; CARTILAGE CELL; CARTILAGE DEGENERATION; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL MOBILITY SHIFT ASSAY; GENE SILENCING; HISTOPATHOLOGY; IN VIVO GENE TRANSFER; KNEE LIGAMENT; KNEE OSTEOARTHRITIS; MALE; MENISCECTOMY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYNOVIAL FLUID LEVEL; SYNOVIUM; WESTERN BLOTTING;

ADENOVIRIDAE; ANIMALS; ARTHRITIS, EXPERIMENTAL; CARTILAGE, ARTICULAR; CHONDROCYTES; GENE THERAPY; GENETIC VECTORS; INTERLEUKIN-1BETA; NF-KAPPA B; OSTEOARTHRITIS, KNEE; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SYNOVIAL FLUID; TUMOR NECROSIS FACTOR-ALPHA;

EID: 38949205532     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joca.2007.06.006     Document Type: Article

References (61)

1. Pelletier J.P., Martel-Pelletier J., and Howe D.S. Etiopathogenesis of osteoarthritis. In: Koopman W.J. (Ed). Arthritis and Allied Conditions. A textbook of Rheumatology. 13 edn. (1997), Williams & Wilkins, Baltimore 1969-1984
2. Saklatvala J. Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 322 (1986) 547-549
3. Pelletier J.P., McCollum R., Cloutier J.M., and Martel-Pelletier J. Synthesis of metalloproteases and interleukin 6 (IL-6) in human osteoarthritic synovial membrane is an IL-1 mediated process. J Rheumatol 22 (1995) 109-114
4. Evens C., and Robbins P.D. Prospects for treating arthritis by gene therapy. J Rheumatol 21 (1994) 779-782
5. Robbins P.D., and Evens C.H. Prospects for treating autoimmune and inflammatory disease by gene therapy. Gene Ther 3 (1996) 187-189
6. Pang G., Couch L., Batey R., Clancy R., and Cripps A. GM-CSF, IL-1α, IL-1β, IL-6, IL-8, IL-10, ICAM-1 and VCAM-1 gene expression and cytokine production in human duodenal fibroblasts stimulated with lipopolysaccharide, IL-1α and TNF-α. Clin Exp Immunol 96 (1994) 437-443
7. Karin M., and Delhase M. The IkB kinase (IKK) and NF-kB: key elements of proinflammatory signalling. Semin Immunol 12 (2000) 85-98
8. Thomas B., Berenbaum F., Humbert L., Bian H., Bereziat G., Crofford L., et al. Critical role of C/EBPδ and C/EBPβ factors in the stimulation of the cyclooxygenase-2 gene transcription by interleukin-1β in articular chondrocytes. Eur J Biochem 267 (2000) 798-809
9. Vincenti M.P., and Brinckerhoff C.E. Early response genes induced in chondrocytes stimulated with the inflammatory cytokine interleukin-1β. Arthritis Res 3 (2001) 381-388
10. Westacott C.I., and Sharif M. Cytokines in osteoarthritis: mediators or markers of joint destruction?. Semin Arthritis Rheum 25 (1996) 254-272
11. Evans C.H., and Robbins P.D. Potential treatment of osteoarthritis by gene therapy. Rheum Dis Clin North Am 25 (1999) 333-344
12. Baragi V.M. Technology evaluation: MFG-IRAP, University of Pittsburgh. Curr Opin Mol Ther 2 (2000) 216-220
13. Attur E.G., Dave M.N., Leung M.Y., Cipolletta C., Meseck M., Woo S.L., et al. Functional genomic analysis of type II IL-1beta decoy receptor: potential for gene therapy in human arthritis and inflammation. J Immunol 168 (2002) 2001-2010
14. Frisbie D.D., Ghivizzani S.C., Robbins P.D., Evans C.H., and McIlwraith C.W. Treatment of equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene. Gene Ther 9 (2002) 12-20
15. Chikanza I., and Femandes L. Novel strategies for the treatment of osteoarthritis. Expert Opin Investig Drugs 9 (2000) 1499-1510
16. Janusz M.J., Hookfin E.B., Heitmeyer S.A., Woessner J.F., Freemont A.J., Hoyland J.A., et al. Moderation of iodoacetate-induced experimental osteoarthritis in rats by matrix metallo-proteinase inhibitors. Osteoarthritis Cartilage 9 (2001) 751-760
17. De-Maetin R., Hoeth M., Hofer-Warbinek R., and Schmid J.A. The transcription factor NF-κB and the regulation of vascular cell function. Arterioscler Thromb Vasc Biol 20 (2000) E83-E88
18. Karin M., and Lin A. NF-kappa B at the crossroads of life and death. Nat Immunol 3 (2002) 221-227
19. Lianxu C., Hongti J., and Changlong Y. NF-κBp65-specific siRNA inhibits expression of genes of COX-2, NOS-2 and MMP-9 in rat IL-1β-induced and TNF-α-induced chondrocytes. Osteoarthritis Cartilage 4 (2006) 367-376
20. Brummelkamp T.R., Bernards R., and Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 296 (2002) 550-553
21. Paddison P.J., Caudy A.A., and Hannon G.J. Stable suppression of gene expression by RNAi in mammalian cells. Proc Natl Acad Sci USA 99 (2002) 1443-1448
22. Sui G., Soohoo C., Affarel B., Gay F., Shi Y., and Forrester W.C. A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc Natl Acad Sci USA 99 (2002) 5515-5520
23. Barton G.M., and Medzhitov R. Retroviral delivery of small interfering RNA into primary cells. Proc Natl Acad Sci USA 99 (2002) 14943-14945
24. Devroe E., and Silver P.A. Retrovirus-delivered siRNA. BMC Biotechnol 2 (2002) 15
25. Shen C., Buck A.K., Liu X., Winkler M., and Reske S.N. Gene silencing by adenovirus-delivered siRNA. FEBS Lett 539 (2003) 111-114
26. Xia H., Mao Q., Paulson H.L., and Davidson B.L. siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol 20 (2002) 1006-1010
27. Tomar R.S., Matta H., and Chaudhary P.M. Use of adeno-associated viral vector for delivery of small interfering RNA. Oncogene 22 (2003) 5712-5715
28. Gouze J.N., Gouze E., Palmer G.D., Kaneto H., Ghivizzani S.C., Grodzinsky A.J., et al. Adenovirus-mediated gene transfer of glutamine: fructose-6-phosphate amidotransferase antagonizes the effects of interleukin-1 beta on rat chondrocytes. Osteoarthritis Cartilage 2 (2004) 217-224
29. Sommerlath K.G., and Gillquist J. The effect of anterior cruciate ligament resection and immediate or delayed implantation of a meniscus prosthesis on knee joint biomechanics and cartilage. An experimental study in rabbits. Clin Orthop 289 (1993) 267-275
30. Bove S.E., Calcaterra S.L., Brooker R.M., Huber C.M., Guzman R.E., Juneau P.L., et al. Weight bearing as a measure of disease progression and efficacy of anti-inflammatory compounds in a model of monosodium iodoacetate-induced osteoarthritis. Osteoarthritis Cartilage 11 (2003) 821-830
31. Pond M.J., and Nuki G. Experimentally-induced osteoarthritis in the dog. Ann Rheum Dis 32 (1973) 287-288
32. Little C., Smith S., Ghosh P., and Bellenger C. Histomorphological and immunohistochemical evaluation of joint changes in a model of osteoarthritis induced by lateral meniscectomy in sheep. J Rheumatol 24 (1997) 2199-2209
33. Moskowitz R.W., Davis W., Sammaraco J., Martens M., Baker J., Mayor M., et al. Experimentally induced degenerative joint lesions following partial meniscectomy in the rabbit. Arthritis Rheum 16 (1973) 397-405
34. Bendele A.M., and White S.L. Early histopathologic and ultrastructural alterations in femorotibial joints of partial medial meniscectomied guinea pigs. Vet Pathol 24 (1987) 436-443
35. Bendele A.M., McComb J., Gould T., McAbee T., Sennello G., Chipala E., et al. Animal models of arthritis: relevance to human disease. Toxicol Pathol 27 (1999) 134-142
36. Stoop R., Buma P., van der Kraan P.M., Hollander A.P., Billinghurst R.C., Meijers T.H.M., et al. Type 2 collagen degeneration in articular cartilage fibrillation after anterior cruciate ligament transaction in rats. Osteoarthritis Cartilage 9 (2001) 308-315
37. Janusz M.J., Bendele A.M., Brown K.K., Taiwo Y.O., Hsieh L., and Heitmeyer S.A. Induction of osteoarthritis in the rat by surgical tear the meniscus: inhibition of joint damage by a matrix metalloproteinase inhibitor. Osteoarthritis Cartilage 10 (2002) 785-791
38. Sandra K., Leo A.B.J., Alison M.B., Carl K.E., Onno J.A., Monique M.A., et al. Different roles of tumour necrosis factor-α and interleukin 1 in murine streptococcal cell wall arthritis. Cytokine 10 (1998) 690-702
39. Bettinger D.A., Pellicane J.V., and Tarry W.C. The role of inflammatory cytokines in wound healing: accelerated healing in endotoxin-resistant mice. J Trauma 36 (1994) 810-814
40. Elliot M.J., Maini R.N., Feldmann M., Kalden J.R., Antoni C., Smolen J., et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344 (1994) 1105-1110
41. Rankin E.C.C., Choy E.H.S., Kassimos D., Kingsley G.H., Sopwith A.M., Isenberg D.A., et al. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol 34 (1995) 334-342
42. Campion G.V., Lebsack M.E., Lookabaugh J., Gordon G., and Catalano M. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum 39 (1996) 1092-1101
43. Bresnihan B., Lookabaugh J., Witt K., and Musikic P. Treatment with recombinant human interleukin-1 receptor antagonist in rheumatoid arthritis: results of randomized double-blind, placebo-controlled multicenter trial. Arthritis Rheum 39 (1996) 73
44. Julio F., Ginette T., Johanne M.P., Viorica L.C., Martine D., Florina M., et al. In vivo transfer interleukin-1 receptor antagonist gene in osteoarthritis rabbit knee joints. Am J Pathol 154 (1999) 1159-1169
45. Seon H.K., Eric R.L., Sunyoung K., Joan N., Thomas J.O., and Panl D.R. Ex vivo gene delivery of IL-Ra and soluble TNF receptor confers a synergistic therapeutic effect in antigen-induced arthritis. Mol Ther 6 (2002) 591-600
46. Barnes P.J. Molecules in focus: nuclear factor-kappaB. Int J Biochem Cell Biol 29 (1997) 867-870
47. Tetsuya K., Eiji T., Naruya T., Ryuichi M., Motoharu K., Kei Y., et al. Suppressed severity of collagen-induced arthritis by in vivo transfection of nuclear factor kappa B decoy oligodeoxynucleotides as a gene therapy. Arthritis Rheum 42 (1999) 2532-2542
48. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., and Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411 (2001) 494-498
49. Layzer J.M., McCaffrey A.P., Tanner A.K., Huang Z., Kay M.A., and Sullenger B.A. In vivo activity of nuclease resistant siRNAs. RNA 10 (2004) 766-771
50. Hong J., Qian Z., Shen S., Min T., Tan C., Xu J., et al. High doses of siRNAs induce eri-1 and adar-1 gene expression and reduce the efficiency of RNA interference in the mouse. Biochem J 390 (2005) 675-679
51. Morrissey D.V., Blanchard K., Shaw L., Jensen K., Lockridge J.A., Dickinson B., et al. Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology 41 (2005) 1349-1356
52. Makimura H., Mizuno T.M., Mastaitis J.W., Agami R., and Mobbs C.V. Reducing hypothalamic AGRP by RNA interference increases metabolic rate and decreases body weight without influencing food intake. BMC Neurosci 3 (2002) 18
53. Smith G.M., and Romero M.I. Adenoviral-mediated gene transfer to enhance neuronal survival, growth, and regeneration. J Neurosci Res 55 (1999) 147-157
54. Uchida H., Tanaka T., Sasaki K., Kato K., Dehari H., Ito Y., et al. Adenovirus-mediated transfer of siRNA against survivin induced apoptosis and attenuated tumor cell growth in vitro and in vivo. Mol Ther 10 (2004) 162-171
55. Lakka S.S., Gondi C.S., Dinh D.H., Olivero W.C., Gujrati M., Rao V.H., et al. Specific interference of urokinase-type plasminogen activator receptor and matrix metalloproteinase-9 gene expression induced by double-stranded RNA results in decreased invasion, tumor growth, and angiogenesis in gliomas. J Biol Chem 280 (2005) 21882-21892
56. Ollivier M., Denins G., and Mark P.M. RNA interference in biology and medicine. Pharmacol Rev 55 (2003) 629-648
57. Gelse K., Jiang Q.J., Aigner T., Ritter T., Wagner K., Pöschl E., et al. Fibroblast-mediated delivery of growth factor complementary DNA into mouse joints induces chondrogenesis but avoids the disadvantages of direct viral gene transfer. Arthritis Rheum 44 (2001) 1943-1953
58. Kuboki T., Nakanishi T., Kanyama M., Sonoyama W., Fujisawa T., Kobayashi K., et al. Direct adenovirus-mediated gene delivery to the temporomandibular joint in guinea-pigs. Arch Oral Biol 44 (1999) 701-709
59. Vane J.R., and Botting R.M. The mechanism of action of aspirin. Thromb Res 110 (2003) 255-258
60. Rainer A., and Peskar B.A. Anti-inflammatory effects of aspirin and sodium salicylate. Eur J Pharmacol 447 (2002) 1-9
61. Ozgur K., and Huveyda B. Aspirin inhibits TNFα- and IL-1-induced NF-κB activation and sensitizes HeLa cells to apoptosis. Cytokine 25 (2004) 229-237